NEW YORK, September 17 /PRNewswire/ --

Xenomics, Inc. (Pink Sheets: XNOM; FWB: XE7), a developer of
next-generation medical DNA diagnostic technologies, announced today that it
has signed a licensing agreement with Ipsogen SAS, a leading molecular
diagnostics company based in France and Connecticut for the co-exclusive
rights to develop, manufacture and market research and diagnostic products
for the stratification and monitoring of patients with Acute Myeloid Leukemia
(AML).

AML is a clinically and molecularly heterogeneous disease with about
13,500 new cases per year in the US and a similar number in Europe. The
disease subgrouping by cytogenetic karyotyping indicates patient prognosis.
However, in almost half of AML cases the karyotype appears normal. A recent
discovery by Drs. Falini and Mecucci at the Institute of Hematology at the
University of Perugia in Italy showed that about 60% of adult AML with normal
karyotype have a mutation in the nucleophosmin (NPM1) gene.

Xenomics has obtained an exclusive license for the discovery and
developed a test that detects all known 45 mutations of NPM1 in one reaction.
This diagnostic assay has been implemented in the US at CLIA-approved BRT
Laboratories Inc. in Baltimore, Maryland, and is available for hematologists
and clinicians. In addition, Xenomics scientists have developed a sensitive
NPM1 monitoring test that can detect the presence of residual disease
following chemotherapy. The combination of NPM1 diagnostic and monitoring
assays can provide effective means of assessing and stratifying patients
during ongoing clinical trials. The NIH currently lists 358 clinical trials
for AML approved by human subject review boards.

"Xenomics is committed to expanding patient access to the NPM1 marker
worldwide," said Dr. Samuil Umansky, Chief Scientific Officer of Xenomics,
Inc. "With this acute disease, physicians need a rapid assessment of patient
prognosis for effective use of chemotherapy. NPM1 provides an excellent test
for monitoring the minimal residual disease and patient response to
anti-tumor therapy."

"This agreement with Xenomics, a leading company developing innovative
DNA-based tests, enables Ipsogen to further expand its unique range of
diagnostic products dedicated to the disease management of blood cancers"
said Vincent Fert, president and CEO of Ipsogen. "The NPM1 products will
integrate Ipsogen quantitative and standardized technology (FusionQuant(R)
and ProfileQuant(R)) to warrant the highest level of precision and quality
for clinical laboratories and patients. The NPM1 test results have the
potential to help physicians with prognosis of the disease and with the
monitoring of the patient response to therapy".

About Xenomics, Inc.

Xenomics is a molecular diagnostics company that focuses on the
development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics'
patented technology uses safe and simple urine collection and can be applied
to a broad range of applications, including prenatal testing, tumor detection
and monitoring, tissue transplantation, infectious disease detection, genetic
testing for forensic identity determination, drug development, and research
to counter bioterrorism. Scientists from Xenomics were the first to report
that fragments of DNA from normal cell death cross the kidney barrier and can
be detected in urine. The Company believes that its technology will open
significant new markets in the molecular diagnostics field. Xenomics has
three issued U.S. patents covering different applications of the technology
for molecular diagnostics and genetic testing and a European patent for the
Company's prenatal testing applications, and numerous pending patent
applications. For more investor-specific information, including daily and
historical Company stock quote data, recent news releases and an Investor
Fact Sheet, please visit http://www.xenomics.com. Xenomics is also listed on
the Frankfurt Stock Exchange under the symbol XE7.

About Ipsogen SAS

Ipsogen is a molecular diagnostic company focused on the development and
commercialization of innovative diagnostic products to guide and personalize
treatment options in cancers. Ipsogen has built a comprehensive portfolio of
unique products in blood cancers available in over 50 countries all over the
world to leading institutions involved in cancer care. Ipsogen products are
registered as IVD in Europe. Ipsogen recently established commercial and
service agreements with major testing laboratories in the United States,
Canada and Europe - Laboratory Corporation of America (R) holding
(LabCorp(R)), Warnex Inc. and DNA Vision. Ipsogen is headquartered in
Marseille, France and has its U.S. offices in New Haven, Connecticut. For
more information, please visit http://www.ipsogen.com.

Contact:
    David Robbins
    V.P., Product Development
    Xenomics, Inc.
    1-908-489-9182
    DRobbins@Xenomics.com

    Vincent Fert
    President and CEO
    Ipsogen SAS
    +33-0-4-91-29-30-90
    fert@ipsogen.com



Forward-Looking Statements

Certain statements made in this press release are forward looking. Such
statements are indicated by words such as "expect," "might," "should,"
"anticipate" and similar words indicating uncertainty in facts and figures.
Although Xenomics believes that the expectations reflected in such
forward-looking statements are reasonable, it can give no assurance that such
expectations reflected in such forward-looking statements will prove to be
correct. As discussed in Xenomics' Form 10-KSB as filed with the Securities
and Exchange Commission on May 16, 2006 and its other periodic reports,
actual results could differ materially from those projected in the
forward-looking statements as a result of the following factors, among
others: uncertainties associated with product development, the risk that
Xenomics will not obtain approval to market its products, the risk that
Xenomics' technology will not gain market acceptance, the risks associated
with dependence upon key personnel, and the need for additional financing.

Web site: http://www.xenomics.com
              http://www.ipsogen.com